IMUXNasdaqPharmaceutical PreparationsFiscal year ends December 31
IMMUNIC, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026
$6.99+0.02 (+0.29%)
Close on Oct 19, 2026
- Market cap
- $297.17M
- P/E (TTM)
- –
- Dividend yield
- 0.00%
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
63.7%
9M of 14M shares
Institutional holders
55
53 new, 1 sold out
Net institutional buying
8M
In Q2 2026
Insider trades, 12 months
0 buys · 0 sales
Open-market trades only
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Millennium Group Management LLC | 969,547 | 7.00% | 13G (passive) amendment | Jun 30, 2026 |
| Alyeska Investment Group, L.P. | 9,485,936 | 9.90% | 13G (passive) | Jun 30, 2025 |
| Avidity Capital Partners Fund (GP) LP | 9,022,363 | 9.90% | 13G (passive) amendment | Dec 31, 2024 |
| Benjamin Alexander Smith | 839,526 | 6.06% | 13G (passive) | Jun 30, 2026 |
| abrdn Inc. | 8,243,941 | 6.85% | 13G (passive) amendment | Dec 31, 2025 |
| Aberdeen Group plc | 824,393 | 6.05% | 13G (passive) amendment | Jun 30, 2026 |
| Millennium Management LLC | 793,621 | 5.70% | 13G (passive) | Apr 29, 2026 |
| OrbiMed Advisors LLC | 756,860 | 5.30% | 13G (passive) | Jun 30, 2026 |
| 683 Capital Management, LLC | 7,500,000 | 5.90% | 13G (passive) amendment | Dec 31, 2025 |
| Guy Levy | 6,792,000 | 5.50% | 13G (passive) | Feb 17, 2026 |
| Avidity Partners Management LP | 5,615,811 | 5.90% | 13G (passive) amendment | Jun 30, 2025 |
| Vivo Opportunity Fund Holdings, L.P. | 29,126,906 | 9.99% | 13G (passive) | Feb 17, 2026 |
| Michael Kramarz | 1,511,821 | 9.90% | 13G (passive) amendment | Jun 30, 2026 |
| Michael Gregory | 13,958,410 | 9.90% | 13G (passive) | Feb 17, 2026 |
| Lampert Mark N | 13,630,601 | 9.99% | 13D (active) | Feb 12, 2026 |
| Commodore Capital Master LP | 13,350,121 | 9.90% | 13G (passive) | Feb 17, 2026 |
| Janus Henderson Group PLC | 12,016,444 | 9.99% | 13G (passive) | Nov 28, 2025 |
| Deep Track Capital, LP | 11,454,000 | 8.69% | 13G (passive) | Feb 17, 2026 |
| Trails Edge Biotechnology Master Fund, LP | 11,454,000 | 8.70% | 13G (passive) | Feb 17, 2026 |
| Anand Parekh | 11,250,000 | 9.35% | 13G (passive) amendment | Sep 30, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of IMUX | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| abrdn plc | 824,393 | 6.04% | $12.67M | New | 0.02% |
| Bvf Inc/Il | 765,295 | 5.61% | $11.76M | New | 0.30% |
| Millennium Management LLC | 740,347 | 5.43% | $11.38M | New | 0.00% |
| Avidity Partners Management LP | 669,941 | 4.91% | $10.30M | New | 1.65% |
| Braidwell LP | 645,010 | 4.73% | $9.91M | New | 0.37% |
| Laurion Capital Management LP | 610,326 | 4.47% | $9.38M | New | 0.24% |
| Vanguard Capital Management LLC | 571,561 | 4.19% | $8.78M | New | 0.00% |
| Jones Hill Capital LP | 539,814 | 3.96% | $8.30M | New | 1.76% |
| Nantahala Capital Management, LLC | 501,292 | 3.67% | $7.70M | New | 0.13% |
| Woodline Partners LP | 471,528 | 3.46% | $7.25M | New | 0.02% |
| Soleus Capital Management, L.P. | 450,000 | 3.30% | $6.92M | New | 0.24% |
| Propel Bio Management, LLC | 325,022 | 2.38% | $5.00M | New | 2.61% |
| UBS Group AG | 175,756 | 1.29% | $2.70M | New | 0.00% |
| Geode Capital Management, LLC | 170,675 | 1.25% | $2.62M | New | 0.00% |
| 683 Capital Management, LLC | 147,245 | 1.08% | $2.26M | New | 0.11% |
| Adage Capital Partners Gp, L.L.C. | 139,860 | 1.03% | $2.15M | New | 0.00% |
| BlackRock, Inc. | 132,791 | 0.97% | $2.04M | New | 0.00% |
| Marshall Wace, Llp | 104,816 | 0.77% | $1.61M | −848,150 | 0.00% |
| Susquehanna International Group, Llp | 90,890 | 0.67% | $1.40M | New | 0.00% |
| Jane Street Group, LLC | 89,687 | 0.66% | $1.38M | New | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 55 | 9M | 63.7% | 53 / 1 | 1 / 1 | 9M | 1M |
| Q1 2026 | 3 | 1M | 7.0% | 3 / 0 | 0 / 0 | 1M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of IMUX | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 399,088 | 2.92% | $6.13M | 0.00% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 159,248 | 1.17% | $2.45M | 0.00% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 63,010 | 0.46% | $942.63K | 0.00% | May 31, 2026 |
| iShares Micro-Cap ETF | 46,243 | 0.34% | $710.75K | 0.05% | Jun 30, 2026 |
| Simplify Propel Opportunities ETF | 30,725 | 0.23% | $472.24K | 0.61% | Jun 30, 2026 |
| Fidelity Total Market Index Fund | 29,253 | 0.21% | $437.62K | 0.00% | May 31, 2026 |
| Fidelity Series Total Market Index Fund | 17,808 | 0.13% | $266.41K | 0.00% | May 31, 2026 |
| Fidelity Nasdaq Composite Index Fund | 9,839 | 0.07% | $147.19K | 0.00% | May 31, 2026 |
| Schwab Total Stock Market Index Fund | 8,500 | 0.06% | $118.75K | 0.00% | Jul 31, 2026 |
| Fidelity ZERO Total Market Index Fund | 8,037 | 0.06% | $112.28K | 0.00% | Jul 31, 2026 |
| Vanguard Institutional Total Stock Market Index Fund | 6,993 | 0.05% | $107.48K | 0.00% | Jun 30, 2026 |
| Vanguard Balanced Index Fund | 6,232 | 0.05% | $95.79K | 0.00% | Jun 30, 2026 |
| Fidelity ZERO Extended Market Index Fund | 5,154 | 0.04% | $72.00K | 0.00% | Jul 31, 2026 |
| 1290 VT Micro Cap Portfolio | 3,121 | 0.02% | $47.97K | 0.02% | Jun 30, 2026 |
| Fidelity Flex Small Cap Index Fund | 2,207 | 0.02% | $30.83K | 0.01% | Jul 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Duane Nash | Executive Chairman, Director | 45,256 | 0.33% | Jul 18, 2025 |
| Jason Tardio | President and COO | 12,512 | 0.09% | Jun 29, 2026 |
| Glenn Whaley | Chief Financial Officer | 95,510 | 0.70% | Jun 29, 2026 |
| Erik Lundgren | Chief Executive Officer | – | – | Jun 1, 2026 |
| Michael A. Panzara | Chief Medical Officer | – | – | Apr 29, 2026 |
| Andreas Muehler | Chief Medical Officer | 582,466 | 4.27% | Jul 18, 2025 |
| Value Trading Fund OS LP Biotechnology | Director | 427,629 | 3.13% | Sep 18, 2026 |
| Partners L. P/Il Bvf | Director | – | – | Sep 18, 2026 |
| Value Fund L. P. Biotechnology | Director | – | – | Sep 18, 2026 |
| Partners OS Ltd. BVF | Director | – | – | Sep 18, 2026 |
| Ii Gp Llc Bvf | Director | – | – | Sep 18, 2026 |
| Robert Thorvald Nagel | Director | – | – | Sep 18, 2026 |
| Value Fund Ii Lp Biotechnology | Director | – | – | Sep 18, 2026 |
| I. Gp Llc Bvf | Director | – | – | Sep 18, 2026 |
| Inc/Il Bvf | Director | – | – | Sep 18, 2026 |
| Mark N. Lampert | Director | – | – | Sep 18, 2026 |
| Gp Holdings Llc Bvf | Director | 42,762 | 0.31% | Sep 18, 2026 |
| Elena Ridloff | Director | – | – | Aug 10, 2026 |
| Jon Congleton | Director | – | – | Jul 7, 2026 |
| Richard Alan Rudick | Director | 230,375 | 1.69% | Jul 7, 2026 |
| Barclay A. Phillips | Director | – | – | Jul 7, 2026 |
| Joerg Neermann | Director | 200,000 | 1.47% | Jul 7, 2026 |
| Simona Skerjanec | Director | – | – | Jul 7, 2026 |
| Michael W. Bonney | Director | – | – | Jun 29, 2026 |
| Daniel Vitt | Director | 391,877 | 2.87% | Jun 29, 2026 |
| Tamar D. Howson | Director | – | – | Jun 29, 2026 |
| Monika Maria Toernsen | Director | – | – | Jun 9, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Duane Nash Executive Chairman, Director | Jun 13, 2025 | Buy | +20,000 | $0.83 | $16.60K | 36,032 |
| Jason Tardio President and COO | Jun 5, 2025 | Buy | +12,512 | $0.79 | $9.88K | 12,512 |
| Jason Tardio President and COO | Jun 5, 2025 | Buy | +12,512 | $0.79 | $9.88K | 12,512 |
| Joerg Neermann Director | Jun 5, 2025 | Buy | +30,000 | $0.76 | $22.80K | 200,000 |
| Daniel Vitt CEO and Director | Jun 4, 2025 | Buy | +15,000 | $0.77 | $11.55K | 29,000 |
| Daniel Vitt CEO and Director | Jun 4, 2025 | Buy | +15,000 | $0.77 | $11.55K | 29,000 |
| Joerg Neermann Director | Jun 4, 2025 | Buy | +70,000 | $0.77 | $53.90K | 170,000 |
| Glenn Whaley Chief Financial Officer | Jun 3, 2025 | Buy | +45,000 | $0.71 | $31.95K | 95,510 |
| Richard Alan Rudick Director | Jun 3, 2025 | Buy | +143,075 | $0.70 | $100.15K | 230,375 |
| Glenn Whaley Chief Financial Officer | May 30, 2025 | Award | +25,000 | $0.56 | $14.00K | 50,510 |
| Richard Alan Rudick Director | Nov 12, 2024 | Buy | +87,300 | $1.15 | $100.39K | 87,300 |
| Daniel Vitt President and CEO, Director | Feb 26, 2024 | Buy | +14,000 | $1.31 | $18.34K | 390,877 |
| Glenn Whaley Chief Financial Officer | May 15, 2023 | Buy | +5,000 | $1.75 | $8.75K | 25,510 |
| Joerg Neermann Director | Dec 14, 2022 | Buy | +47,000 | $1.26 | $59.22K | 100,000 |
| Joerg Neermann Director | Dec 13, 2022 | Buy | +35,000 | $1.25 | $43.75K | 53,000 |
| Joerg Neermann Director | Nov 23, 2022 | Buy | +18,000 | $1.39 | $25.02K | 18,000 |
| Daniel Vitt President and CEO, Director | Nov 22, 2022 | Buy | +8,000 | $1.35 | $10.80K | 376,877 |
| Glenn Whaley Chief Financial Officer | Nov 7, 2022 | Buy | +5,000 | $1.50 | $7.50K | 20,510 |
| Daniel Vitt President and CEO, Director | Jun 3, 2022 | Buy | +5,000 | $3.10 | $15.50K | 368,877 |
| Glenn Whaley Chief Financial Officer | Jun 3, 2022 | Buy | +3,500 | $3.05 | $10.68K | 12,568 |
| Andreas Muehler Chief Medical Officer | May 12, 2022 | Buy | +3,500 | $5.10 | $17.85K | 297,986 |
| Glenn Whaley Chief Financial Officer | May 12, 2022 | Buy | +3,000 | $5.08 | $15.24K | 9,068 |
| Duane Nash Executive Chairman, Director | May 12, 2022 | Buy | +10,000 | $5.03 | $50.30K | 22,032 |
| Duane Nash Executive Chairman, Director | May 12, 2022 | Gift | −6,000 | – | – | 16,032 |
| Duane Nash Executive Chairman, Director | Nov 8, 2021 | Gift | −3,000 | – | – | 12,032 |
| Daniel Vitt President and CEO, Director | Aug 10, 2021 | Buy | +1,000 | $9.60 | $9.60K | 363,877 |
| Duane Nash Executive Chairman, Director | Aug 10, 2021 | Buy | +1,000 | $9.80 | $9.80K | 15,032 |
| Glenn Whaley PFO and PAO | Aug 10, 2021 | Buy | +1,500 | $9.85 | $14.78K | 3,500 |
| Duane Nash Executive Chairman, Director | May 12, 2021 | Buy | +4,000 | $12.75 | $51.00K | 14,032 |
| Andreas Muehler Chief Medical Officer | Mar 2, 2021 | Buy | +10,006 | $15.54 | $155.49K | 294,486 |
| Glenn Whaley PFO and PAO | Mar 2, 2021 | Buy | +1,000 | $16.48 | $16.48K | 2,000 |
| Glenn Whaley PFO and PAO | Aug 10, 2020 | Buy | +1,000 | $18.96 | $18.96K | 1,000 |
| Manfred Groeppel Chief Operating Officer | Jul 21, 2020 | Sale(10b5-1 plan) | −650 | $15.62 | $10.15K | 278,830 |
| Daniel Vitt Chief Executive Officer, Director | Jul 21, 2020 | Sale(10b5-1 plan) | −1,300 | $15.62 | $20.31K | 362,877 |
| Manfred Groeppel Chief Operating Officer | Jul 20, 2020 | Sale(10b5-1 plan) | −5,000 | $14.44 | $72.20K | 279,480 |
| Daniel Vitt Chief Executive Officer, Director | Jul 20, 2020 | Sale(10b5-1 plan) | −5,000 | $14.44 | $72.20K | 364,177 |
| Duane Nash Director | Dec 4, 2019 | Sale(10b5-1 plan) | −4,400 | $6.96 | $30.62K | 10,032 |
| Duane Nash Director | Dec 3, 2019 | Tax withholding | −7,930 | $7.15 | $56.70K | 14,432 |
| Duane Nash Director | Dec 2, 2019 | Option exercise | +22,157 | – | – | 22,362 |
| Errol R. Halperin Director | Sep 25, 2018 | Sale | −89,417 | $0.29 | $25.93K | 0 |
| Errol R. Halperin Director | Sep 25, 2018 | Sale | −10,000 | $0.29 | $2.90K | 0 |
| Jean Jacques Bienaime Director | Sep 24, 2018 | Sale | −26,619 | $0.30 | $7.99K | 18,500 |
| Douglas Evan Godshall Director | Sep 19, 2018 | Sale | −69,375 | $0.35 | $24.28K | 0 |
| Muneer A. Satter Director, 10% owner | Sep 17, 2018 | Sale | −7,044,777 | $0.29 | $2.04M | 0 |
| Muneer A. Satter Director, 10% owner | Sep 14, 2018 | Sale | −447,500 | $0.36 | $161.10K | 7,044,777 |
| Faheem Hasnain Director | Sep 13, 2018 | Sale | −59,200 | $0.44 | $26.05K | 122,743 |
| Faheem Hasnain Director | Sep 13, 2018 | Sale | −118,243 | $0.44 | $52.03K | 4,500 |
| Jean Jacques Bienaime Director | Sep 13, 2018 | Sale | −20,000 | $0.47 | $9.40K | 45,119 |
| Muneer A. Satter Director, 10% owner | Sep 13, 2018 | Sale | −3,890,000 | $0.50 | $1.95M | 7,492,277 |
| Cheryl Cohen Director | Sep 12, 2018 | Sale | −3,500 | $0.55 | $1.93K | 0 |
| Muneer A. Satter Director, 10% owner | Dec 13, 2017 | Buy | +50,000 | $5.57 | $278.50K | 11,382,277 |
| Muneer A. Satter Director, 10% owner | Dec 12, 2017 | Buy | +50,000 | $5.40 | $270.00K | 11,332,277 |
| Muneer A. Satter Director, 10% owner | Dec 11, 2017 | Buy | +50,000 | $4.96 | $248.00K | 11,282,277 |
| Muneer A. Satter Director, 10% owner | Dec 8, 2017 | Buy | +50,000 | $4.92 | $246.00K | 11,232,277 |
| Muneer A. Satter Director, 10% owner | Dec 7, 2017 | Buy | +50,000 | $4.77 | $238.50K | 11,182,277 |
| Faheem Hasnain Director | Sep 14, 2017 | Buy | +59,200 | $4.19 | $248.05K | 181,943 |
| Muneer A. Satter Director, 10% owner | Sep 14, 2017 | Buy | +30,000 | $4.25 | $127.50K | 11,132,277 |
| Muneer A. Satter Director, 10% owner | Sep 13, 2017 | Buy | +50,000 | $4.13 | $206.50K | 11,102,277 |
| Jean Jacques Bienaime Director | Sep 13, 2017 | Buy | +10,000 | $4.00 | $40.00K | 65,119 |
| Muneer A. Satter Director, 10% owner | Sep 12, 2017 | Buy | +50,000 | $3.74 | $187.00K | 11,052,277 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.